PHARMACY-MANAGED, WEIGHT-BASED HEPARIN PROTOCOL

被引:33
作者
RIVEY, MP [1 ]
PETERSON, JP [1 ]
机构
[1] COMMUNITY MED CTR,MISSOULA,MT
来源
AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1993年 / 50卷 / 02期
关键词
ANTICOAGULANTS; DOSAGE; DOSAGE SCHEDULES; HEPARIN; PHARMACY; INSTITUTIONAL; HOSPITAL; PROTOCOLS; WEIGHT;
D O I
10.1093/ajhp/50.2.279
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A revised protocol for heparin therapy, in which dosing was based on the patient's weight and the pharmacy staff assumed responsibility for management of the treatment protocol, was evaluated. A fixed-dose protocol for heparin therapy, in which an initial loading dose and infusion rate were specified by physicians and partial thromboplastin times (PTTs) were determined every 12 hours, was revised to determine dosing based on patient weight and diagnosis and to include more levels of dose adjustment and additional laboratory tests. Data on demographic characteristics of patients, heparin therapy, laboratory monitoring, conversion to warfarin therapy, and protocol management were collected for the patients receiving heparin under the revised protocol. Results were compared with those obtained for the old, fixed-dose protocol, which was managed by nursing staff. The revised protocol showed improvements in heparin therapy according to commonly accepted treatment criteria, including dosages, time to achieve a PTT associated with therapeutic anticoagulation, and the time a patient was in the target PTT range. The new protocol was also significantly more effective in avoiding low as well as high PTT ratios. The laboratory monitoring mandated by the revised protocol enhanced the monitoring of heparin therapy, and pharmacy management improved the accuracy and documentation of heparin therapy. Under the revised protocol, anticoagulation goals were attained more rapidly, and dosing changes were more likely to be correct and appropriately documented.
引用
收藏
页码:279 / 284
页数:6
相关论文
共 13 条
[1]  
CARTER BL, 1991, CLIN PHARMACY, V10, P503
[2]  
CIPOLLE RJ, 1986, APPLIED PHARMACOKINE, P903
[3]   A STANDARD HEPARIN NOMOGRAM FOR THE MANAGEMENT OF HEPARIN-THERAPY [J].
CRUICKSHANK, MK ;
LEVINE, MN ;
HIRSH, J ;
ROBERTS, R ;
SIGUENZA, M .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (02) :333-337
[4]  
DANIEL WW, 1978, BIOSTATISTICS F ANAL
[5]   HEPARIN KINETICS IN VENOUS THROMBOSIS AND PULMONARY-EMBOLISM [J].
HIRSH, J ;
VANAKEN, WG ;
GALLUS, AS ;
DOLLERY, CT ;
CADE, JF ;
YUNG, WL .
CIRCULATION, 1976, 53 (04) :691-695
[6]  
HIRSH J, 1991, NEW ENGL J MED, V324, P1565
[7]   HEPARIN FOR 5 DAYS AS COMPARED WITH 10 DAYS IN THE INITIAL TREATMENT OF PROXIMAL VENOUS THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
ROSENBLOOM, D ;
PANJU, AA ;
BRILLEDWARDS, P ;
GINSBERG, JS ;
HIRSH, J ;
MARTIN, GJ ;
GREEN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) :1260-1264
[8]   CONTINUOUS INTRAVENOUS HEPARIN COMPARED WITH INTERMITTENT SUBCUTANEOUS HEPARIN IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
HIRSH, J ;
JAY, RM ;
LECLERC, JR ;
GEERTS, WH ;
ROSENBLOOM, D ;
SACKETT, DL ;
ANDERSON, C ;
HARRISON, L ;
GENT, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (18) :1109-1114
[9]   IDENTIFICATION AND PRELIMINARY VALIDATION OF PREDICTORS OF MAJOR BLEEDING IN HOSPITALIZED-PATIENTS STARTING ANTICOAGULANT-THERAPY [J].
LANDEFELD, CS ;
COOK, EF ;
FLATLEY, M ;
WEISBERG, M ;
GOLDMAN, L .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (04) :703-713
[10]  
MCEVOY GK, 1992, AHFS DRUG INFORMATIO